MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline as Securities Case Advances in SDNY

Overview

• The lawsuit is pending in the U.S. District Court for the Southern District of New York as Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612.
• Investors who bought MoonLake stock from March 10, 2024 through September 29, 2025 have until December 15, 2025 to seek appointment as lead plaintiff.
• The complaints assert claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, alleging material misstatements and omissions about sonelokimab.
• Filings contend SLK targets the same cytokines as BIMZELX (IL-17A and IL-17F) and that its touted Nanobody structure did not deliver superior clinical benefit or meaningful efficacy gains.
• After MoonLake reported disappointing VELA week-16 results on September 28, 2025, including VELA-2 missing its primary endpoint, the stock fell nearly 90% by the next trading day and multiple firms issued investor notices while no class has yet been certified.